Structure Therapeutics is a clinical stage global biopharmaceutical company focused on developing and delivering oral therapeutics to treat a range of diseases. Co. focuses on G-protein-coupled receptors as a therapeutic target class. Co. is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor, or GLP-1R, for the treatment of type-2 diabetes mellitus and obesity. Co. is also developing GLP-1R candidates, including dual GLP-1R/GIPR agonists. Co. has completed a Phase 1 single ascending dose and multiple ascending dose study evaluating ANPA-0073, its small molecule product candidate targeting the apelin receptor. The GPCR average annual return since 2023 is shown above.
The Average Annual Return on the GPCR average annual return since 2023 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether GPCR average annual return since 2023 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the GPCR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|